BACKGROUND: There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients. PATIENTS AND METHODS: We retrospectively reviewed the charts of patients ≥75 years old diagnosed with metastatic or unresectable STS between 1991 and 2011 in 11 French and American centers. RESULTS: The study included 361 patients. Of these, 223 patients (62%) received systemic therapy, whereas 123 patients (34%) were managed with best supportive care (BSC) only. Patients who received BSC were more likely to be ≥80 years, with performance status (PS) ≥ 2, Charlson comorbidity score ≥ 10, and metastatic disease. The median progression-free survival of patients treated with systemic therapy was 4 months (95% CI: 2.9-5.1). Thirty-six patients (16%) stopped chemotherapy because of toxicity. Median overall survival (OS) of patients managed with specific therapy was 10.9 months (95% CI: 8.3-13.5) versus 5.3 months (95% CI: 3.6-7.1) for patients managed with BSC (P = 0.001). On multivariate analysis, age ≥ 80 years, PS ≥ 2, and number of metastatic sites were the only independent factors associated with OS. CONCLUSION: A high proportion of elderly patients with advanced STS were denied chemotherapy. Further efforts are needed to define better the optimal care for fit and unfit elderly patients with STS.
BACKGROUND: There are no data regarding the management of advanced soft-tissue sarcoma (STS) in elderly patients. PATIENTS AND METHODS: We retrospectively reviewed the charts of patients ≥75 years old diagnosed with metastatic or unresectable STS between 1991 and 2011 in 11 French and American centers. RESULTS: The study included 361 patients. Of these, 223 patients (62%) received systemic therapy, whereas 123 patients (34%) were managed with best supportive care (BSC) only. Patients who received BSC were more likely to be ≥80 years, with performance status (PS) ≥ 2, Charlson comorbidity score ≥ 10, and metastatic disease. The median progression-free survival of patients treated with systemic therapy was 4 months (95% CI: 2.9-5.1). Thirty-six patients (16%) stopped chemotherapy because of toxicity. Median overall survival (OS) of patients managed with specific therapy was 10.9 months (95% CI: 8.3-13.5) versus 5.3 months (95% CI: 3.6-7.1) for patients managed with BSC (P = 0.001). On multivariate analysis, age ≥ 80 years, PS ≥ 2, and number of metastatic sites were the only independent factors associated with OS. CONCLUSION: A high proportion of elderly patients with advanced STS were denied chemotherapy. Further efforts are needed to define better the optimal care for fit and unfit elderly patients with STS.
Authors: Eugenie Younger; Saskia Litière; Axel Le Cesne; Olivier Mir; Hans Gelderblom; Antoine Italiano; Sandrine Marreaud; Robin Lewis Jones; Alessandro Gronchi; Winette T A van der Graaf Journal: Oncologist Date: 2018-04-12
Authors: Tobias M Ballhause; Alexander Korthaus; Martin Jahnke; Karl-Heinz Frosch; Jin Yamamura; Tobias Dust; Carsten W Schlickewei; Matthias H Priemel Journal: Diagnostics (Basel) Date: 2022-05-21
Authors: Lars H Lindner; Saskia Litière; Stefan Sleijfer; Charlotte Benson; Antoine Italiano; Bernd Kasper; Christina Messiou; Hans Gelderblom; Eva Wardelmann; Axel Le Cesne; Jean-Yves Blay; Sandrine Marreaud; Nadia Hindi; Ingrid M E Desar; Alessandro Gronchi; Winette T A van der Graaf Journal: Int J Cancer Date: 2018-02-14 Impact factor: 7.396
Authors: R L Jones; G D Demetri; S M Schuetze; M Milhem; A Elias; B A Van Tine; J Hamm; S McCarthy; G Wang; T Parekh; R Knoblauch; M L Hensley; R G Maki; S Patel; M von Mehren Journal: Ann Oncol Date: 2018-09-01 Impact factor: 32.976
Authors: Axel Le Cesne; Sebastian Bauer; George D Demetri; Guangyang Han; Luca Dezzani; Qasim Ahmad; Jean-Yves Blay; Ian Judson; Patrick Schöffski; Massimo Aglietta; Peter Hohenberger; Hans Gelderblom Journal: BMC Cancer Date: 2019-08-13 Impact factor: 4.430
Authors: Clémence Basse; Antoine Italiano; Nicolas Penel; Olivier Mir; Claire Chemin; Maud Toulmonde; Florence Duffaud; Axel Le Cesne; Christine Chevreau; Carlos Maynou; Philippe Anract; François Gouin; Maria Rios; Nelly Firmin; Jean-Emmanuel Kurtz; Pierre Kerbrat; Sophie Piperno-Neumann; François Bertucci; Philippe Rosset; Nicolas Isambert; Emmanuelle Bompas; Pascale Dubray-Longeras; Fabrice Fiorenza; Christine Le Maignan; Loïc Chaigneau; Antoine Thyss; Olivier Bouché; Jean-Christophe Eymard; Corinne Delcambre Lair; Julien Adam; Marie Karanian; Céleste Lebbé; Aurélien Dupré; Pierre Meeus; Mehdi Brahmi; Armelle Dufresne; Françoise Ducimetière; Isabelle Ray-Coquard; Jean-Yves Blay Journal: Int J Cancer Date: 2019-04-15 Impact factor: 7.396
Authors: Vlatko Potkrajcic; Frank Traub; Barbara Hermes; Marcus Scharpf; Jonas Kolbenschlag; Daniel Zips; Frank Paulsen; Franziska Eckert Journal: Radiol Oncol Date: 2021-11-19 Impact factor: 2.991